OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY

被引：0

作者：

Seymour, J. F. ^{[1
]}

Doehner, H. ^{[2
]}

Kumar, R. ^{[3
]}

Stone, R. M. ^{[4
]}

Wierzbowska, A. ^{[5
]}

Bernal del Castillo, T. ^{[6
]}

Falantes, J. ^{[7
]}

Delaunay, J. ^{[8
]}

Sabloff, M. ^{[9
,10
]}

Voso, M. T. ^{[11
]}

Kim, I. ^{[12
]}

Ram, R. ^{[13
]}

Gau, J. P. ^{[14
]}

Songer, S. ^{[15
]}

Lucy, L. M. ^{[15
]}

Beach, C. ^{[15
]}

Dombret, H. ^{[16
]}

机构：

[1] Peter MacCallum Canc Ctr, East Melbourne, Australia

[2] Univ Ulm Klinikum, Ulm, Germany

[3] Canc Care Manitoba, Winnipeg, MB, Canada

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Med Univ Lodz, Lodz, Poland

[6] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain

[7] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain

[8] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France

[9] Univ Ottawa, Ottawa, ON, Canada

[10] Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[11] Univ Roma Tor Vergata, Rome, Italy

[12] Seoul Natl Univ Hosp, Seoul 110744, South Korea

[13] Rabin Med Ctr, Petah Tiqwa, Israel

[14] Taipei Vet Gen Hosp, Taipei, Taiwan

[15] Celgene Corp, Summit, NJ USA

[16] Univ Paris Diderot, Inst Univ Hematol, Hop St Louis, Paris, France

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E954

引用

页码：381 / 381

页数：1

共 50 条

[1] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-AML-001 STUDY
Doehner, H.
Selleslag, D.
Cavenagh, J.
Seymour, J. F.
Minden, M.
Recher, C.
Martinelli, G.
Mayer, J.
Font Lopez, P.
Kim, H. -J.
Chou, W. -C.
Kew, A.
Min, Y. H.
Songer, S.
Lucy, L. M.
Beach, C.
Dombret, H.
HAEMATOLOGICA, 2015, 100 : 215 - 216
[2] OVERALL SURVIVAL (SG) AND CLINICAL RESULTS IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (LMA) TREATED WITH AZACITIDINE (AZA) OR WITH INTENSIVE CHEMOTHERAPY (QI) IN AZA-AML-001
Font Lopez, P.
Dombret, H.
Selleslag, D.
Songer, S.
Lucy Lela, M.
Beach, C. L.
Doeher, H.
HAEMATOLOGICA, 2015, 100 : 22 - 23
[3] OVERALL SURVIVAL (OS) WITHOUT COMPLETE REMISSION (CR) IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN THE AZA-AML-001 STUDY
Schuh, A.
Dombret, H.
Sandhu, I.
Seymour, J. F.
Stone, R. M.
Al-Ali, H. K.
Alimena, G.
Lewis, I.
Kyun, S. Sang
Geddes, M.
Cilloni, D.
Je-Hwan, L.
Songer, S.
Lucy, L. M.
Beach, C.
Doehner, H.
HAEMATOLOGICA, 2015, 100 : 219 - 220
[4] Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study
Doehner, Hartmut
Seymour, John F.
Butrym, Aleksandra
Wierzbowska, Agnieszka
Selleslag, Dominik
Lang, Jun Ho
Cavenagh, James D.
Kumar, Rajat
Schuh, Andre C.
Candoni, Anna
Recher, Christian
Sandhu, Irwindeep
Bernal del Castillo, Teresa
Al-Ali, Haifa Kathrin
Martinelli, Giovanni
Falantes, Jose
Stone, Richard M.
Minden, Mark D.
McIntyre, Heidi
Songer, Stephen
Lucy, Lela M.
Beach, C. L.
Dombret, Herve
BLOOD, 2014, 124 (21)
[5] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN ELDERLY PATIENTS (≥75 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML) IN THE AZA-AML-001 STUDY
Seymour, J. F.
Buckstein, R.
Santini, V.
Doehner, H.
Stone, R. M.
Minden, M. D.
Kuo, C. Y.
Ben-Yehuda, D.
Bargay, J.
Songer, S.
Weaver, J.
Beach, C. L.
Dombret, H.
LEUKEMIA RESEARCH, 2017, 55 : S67 - S68
[6] Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study
Seymour, John F.
Buckstein, Rena
Santini, Valeria
Doehner, Hartmut
Stone, Richard M.
Minden, Mark D.
Kuo, Ching-Yuan
Ben-Yehuda, Dina
Bargay, Joan
Songer, Stephen
Weaver, Jerry
Beach, C. L.
Dombret, Herve
BLOOD, 2016, 128 (22)
[7] AZACITIDINE (AZA) IMPROVES OVERALL SURVIVAL (OS) IN WHO ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS WITH LOW BONE MARROW BLAST COUNTS
Fenaux, P. F.
Silverman, L. R.
Mufti, G. J.
Hellstrom-Lindberg, E.
Santini, V.
Gattermann, N.
Sanz, G.
Seymour, J. F.
Gore, S. D.
Dombret, H.
McKenzie, D.
Backstrom, J.
Beach, C. L.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 430 - 431
[8] OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH > 30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY
Doehner, H.
Seymour, J. F.
Butrym, A.
Wierzbowska, A.
Selleslag, D.
Jang, J. H.
Cavenagh, J. D.
Kumar, R.
Schuh, A. C.
Candoni, A.
Recher, C.
Sandhu, I.
Bernal del Castillo, T.
Al-Ali, H. K.
Martinelli, G.
Falantes, J.
Nopenney, R.
Stone, R. M.
Minden, M. D.
McIntyre, H.
Songer, S.
Lucy, L. M.
Beach, C. L.
Dombret, H.
LEUKEMIA RESEARCH, 2015, 39 : S48 - S49
[9] Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)
Tang, Lin
Dolnik, Anna
MacBeth, Kyle J.
Dombret, Herve
Seymour, John F.
Minden, Mark D.
Stone, Richard M.
Beach, C. L.
Dohner, Hartmut
Bullinger, Lars
BLOOD, 2016, 128 (22)
[10] AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYSPLASIA-RELATED CHANGES (MRC) IN AZA-AML-001 PER CENTRAL REVIEW
Seymour, J. F.
Doehner, H.
Schuh, A. C.
Stone, R. M.
Minden, M.
Weaver, J.
Songer, S.
Beach, C.
Dombret, H.
HAEMATOLOGICA, 2016, 101 : 218 - 219

← 1 2 3 4 5 →